首页> 外文期刊>Non-coding RNA Research >Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?
【24h】

Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?

机译:非编码RNA时代的主动脉瓣钙化:革命进入主动脉狭窄管理?

获取原文
           

摘要

Aortic valve stenosis remains the most frequent structural heart disease, especially in the elderly. During the last decade, we noticed an important consideration and a huge number of publications related to the medical and surgical treatment of this disease. However, the molecular aspect of this degenerative issue has also been more widely studied recently. As evidenced in oncologic but also cardiac research fields, the emergence of microRNAs in the molecular screening and follow-up makes them potential biomarkers in the future, for the diagnosis, follow-up and treatment of aortic stenosis. Herein, we present a review on the implication of microRNAs in the aortic valve disease management. After listing and describing the main miRNAs of interest in the field, we provide an outline to develop miRNAs as innovative biomarkers and innovative therapeutic strategies, and describe a groundbreaking pre-clinical study using inhibitors of miR-34a in a pre-clinical model of aortic valve stenosis.
机译:主动脉瓣狭窄仍然是最常见的结构心脏病,特别是在老年人。在过去十年中,我们注意到了重要的考虑因素和与该疾病的医疗和外科治疗有关的大量出版物。然而,最近的这种退行性问题的分子方面也得到了更广泛的研究。如在肿瘤学中所证明的,但也是心脏研究领域,MicroRNA的出现在分子筛查和随访中,将来会使它们成为潜在的生物标志物,用于诊断,随访和治疗主动脉狭窄。在此,我们介绍了对主动脉瓣病理管理中微小RNA的含义的综述。在上市并描述本领域兴趣的主要MIRNA之后,我们提供了开发MIRNA作为创新生物标志物和创新的治疗策略的概述,并描述了在主动脉前临床前模型中使用miR-34a的抑制剂的突破性前研究阀门狭窄。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号